Antibody (Suitable for clinical applications)
Specification | Recommendation |
---|---|
Recommended Dilution (Conc) | 1:50-1:100 |
Pretreatment | Citrate Buffer pH 6.0 |
Incubation Parameters | 30 min at Room Temperature |
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Anaplastic Lymphoma Kinase Information for Pathologists
Summary:
See also NPM-ALK fusion protein. Anaplastic lymphoma kinase gene is at 2p23; protein is called ALK1, CD246. Membrane spanning tyrosine kinase receptor, member of insulin receptor family. Is NOT the same as Ki-1/CD30, contrary to some references. Interpretation: usually cytoplasmic and nuclear staining.
Anaplastic Lymphoma Kinase General Information | |
---|---|
Alternate Names | |
Molecular Weight | |
176.4 kDa | |
Chromosomal Location | |
p23.1 [chr: 2] [chr_start: 29192774] [chr_end: 29921586] [strand: -1] | |
Curated Database and Bioinformatic Data | |
Gene Symbol | ALK |
Entrez Gene ID | 238 |
RefSeq Protein Accession(s) | NP_004295 |
RefSeq mRNA Accession(s) | XM_024452779; NM_001353765; XR_001738688; XM_024452778; NM_004304 |
RefSeq Genomic Accession(s) | NC_000002; NG_009445 |
UniProt ID(s) | Q9UM73 |
PharmGKB ID(s) | PA24719 |
KEGG Gene ID(s) | hsa:238 |
Associated Diseases (KEGG IDs) | A chromosomal aberration involving ALK is found in a form of non-Hodgkin lymphoma. Translocation t(2;5)(p23;q35) with NPM1. The resulting chimeric NPM1-ALK protein homodimerize and the kinase becomes constitutively activated. The constitutively active fusion proteins are responsible for 5-10% of non-Hodgkin lymphomas.; A chromosomal aberration involving ALK is associated with inflammatory myofibroblastic tumors (IMTs). Translocation t(2;11)(p23;p15) with CARS; translocation t(2;4)(p23;q21) with SEC31A.; A chromosomal aberration involving ALK is associated with anaplastic large-cell lymphoma (ALCL). Translocation t(2;17)(p23;q25) with ALO17.; Neuroblastoma 3 (NBLST3) [MIM:613014]: A common neoplasm of early childhood arising from embryonic cells that form the primitive neural crest and give rise to the adrenal medulla and the sympathetic nervous system. {ECO:0000269|PubMed:18724359, ECO:0000269|PubMed:18923523, ECO:0000269|PubMed:18923525, ECO:0000269|PubMed:21242967}. Disease susceptibility is associated with variations affecting the gene represented in this entry.; The ALK signaling pathway plays an important role in glioblastoma, the most common malignant brain tumor of adults and one of the most lethal cancers. It regulates both glioblastoma migration and growth.; A chromosomal aberration involving ALK is found in one subject with colorectal cancer. Translocation t(2;2)(p23.1;p23.3). A 5 million base pair tandem duplication generates an in-frame WDCP-ALK gene fusion. {ECO:0000269|PubMed:22327622}. |
General Description of Anaplastic Lymphoma Kinase . | |
Anaplastic lymphoma kinase (ALK) known as ALK tyrosine kinase receptor or CD246, is a tyrosine kinase receptor. ALK is an important biomarker for diagnosis of non-‐small cell lung cancer (NSCLC). |
There are no reviews yet.